On November 13, Xintian Pharmaceutical announced that the company received 17 institutions such as Shanghai Investment Morgan, Hanlun Investment and Guolianan Fund on November 10, including 5 fund management companies, 4 securities companies and 3 investment companies
.
In the institutional Q&A, how the company can ensure the future growth trend of existing leading products, the company's medium- and long-term planning in research and development, the overall development plan of OTC in the future, and how to control costs have attracted attention
.
Xintian Pharmaceutical said that the company's current leading products have entered the "fast lane of development" with a single product sales scale of more than 100 million, based on the company's long-term adherence to the clinical efficacy-oriented modern innovative Chinese medicine pharmaceutical concept and strict product market selection mechanism, since the expansion of OTC market channels in 2018, the out-of-hospital market with clinical efficacy has achieved remarkable results
.
At the same time, focusing on the long-term strategic development goals, combined with the unique advantages of existing products and years of marketing experience, the company has made corresponding deployments and arrangements in terms of marketing structure and team optimization, comprehensive brand promotion and market channel expansion, and sinking market paving the way, so as to ensure the long-term sustainable and stable growth of existing leading products, and also open the channel
for the subsequent sales increment of second-tier products.
In terms of research and development, the company's research and development is based on clinical value-oriented, mainly grasp two key points: one is to focus on the familiar gynecological field, and the other is to pay attention to the long-term market value trend
of products.
In order to further accelerate the promotion of existing varieties under research and expand the layout of new R&D projects for the future market, it is expected that next year an unprecedented proportion of R&D investment budget will be increased on the basis of existing R&D investment
.
At present, the traditional Chinese medicine industry is in urgent need of innovation and development, and the policy also strongly supports the development of
the traditional Chinese medicine industry.
According to industry statistics, 11 innovative Chinese medicines have been approved so far in 2021, a record high
in the past five years.
For traditional Chinese medicine enterprises, it is very important to increase investment in research and development, which is one of the important signs of innovation ability and also affects the stamina
of enterprise development.
The third quarterly report of 2022 shows that the company's R&D expenses in the first nine months reached 12.
5715 million yuan, a significant
increase from 11.
7147 million yuan at the beginning of the year.
The company's current research projects are mainly divided into four aspects
: innovative Chinese medicine drugs, Chinese medicine formula granules, ancient classic formulas and clinical re-research of marketed products.
Among them, in terms of innovative traditional Chinese medicine drugs, the company has completed three innovative traditional Chinese medicine drugs in phase III clinical trials, and one variety has been undergoing relevant preparations before the marketing authorization application, and it is expected to start submitting marketing authorization applications
in 2023.
Formula granules have now completed the filing of 153 national standard varieties, and it is planned to achieve the goal of completing the filing of 200 varieties by the end of the year, while the company's fully intelligent production line of traditional Chinese medicine formula granules with an annual design capacity of 570 million bags in Guiyang production base will also be completed and put into use
in June 2023.
The effect of the company's brand strategy and OTC promotion is very obvious, and the overall expectation is clear and the trend is good
.
In the future, the company plans to increase the scope of promotion, and the next step is to cover 11 regions and 31 provinces and cities, still adhere to the important starting point of "driving growth with clinical efficacy", and next year will combine the promotion effect of pilot provinces to promote the commercial brand plan to the whole country
.
At the same time, the company will also build a professional marketing team, increase brand launch, strengthen the market drive between varieties, and strive to achieve the channel target
of 50% or more of OTC market sales.
According to the data, Xintian Pharmaceutical is a pharmaceutical company
integrating new drug research and development, drug production and sales.
At present, the company and Yan Kuntai capsules, Kunlishu bitter ginseng gel, Ningyutai Ningyutai capsules, namely Ruixia subtilis oral liquid and other four leading products have achieved a single product market size
of more than 100 million.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
